About
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The company is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The firm operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Annual results
Reported figures, DKK · revenue up 14.0% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 6.3B | 1.2B | 19.0% | — |
| 2024 | 5.5B | 815M | 14.7% | — |
| 2023 | 4.8B | 486M | 10.1% | — |
| 2022 | 4.5B | 335M | 7.4% | — |
| 2021 | 3.9B | 219M | 5.6% | — |
Dividends per share
ALK-B.CO in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for ALK-Abello A/S are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.